Chad M Vanderbilt
Overview
Explore the profile of Chad M Vanderbilt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim D, Vanderbilt C, Yang S, Nandakumar S, Nafa K, Feratovic R, et al.
Nat Commun
. 2025 Jan;
16(1):116.
PMID: 39747849
Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures....
2.
Rekhtman N, Tischfield S, Febres-Aldana C, Lee J, Chang J, Herzberg B, et al.
Cancer Discov
. 2024 Aug;
15(1):83-104.
PMID: 39185963
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic,...
3.
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman A, Bektas A, et al.
J Clin Oncol
. 2024 Jul;
42(28):3339-3349.
PMID: 39038258
PURPOSEThe impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor...
4.
Elkrief A, Mendez-Salazar E, Maillou J, Vanderbilt C, Gogia P, Desilets A, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):143.
PMID: 39014160
Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of...
5.
Dermawan J, Slotkin E, Tap W, Meyers P, Wexler L, Healey J, et al.
Cancer Res
. 2024 Feb;
84(9):1504-1516.
PMID: 38335254
Significance: Chromoplexy is detectable using targeted NGS in a substantial portion of EWSR1-rearranged round cell sarcomas as an early and persistent clonal event, expanding the genomic complexity of fusion-associated sarcomas.
6.
Memon D, Schoenfeld A, Ye D, Fromm G, Rizvi H, Zhang X, et al.
Cancer Cell
. 2024 Jan;
42(2):209-224.e9.
PMID: 38215748
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired...
7.
Abate M, Walch H, Arora K, Vanderbilt C, Fei T, Drebin H, et al.
Ann Surg
. 2023 Jul;
278(4):506-518.
PMID: 37436885
Objective: Here, we characterize differences in the genetic and microbial profiles of GC in patients of African (AFR), European, and Asian ancestry. Background: Gastric cancer (GC) is a heterogeneous disease...
8.
Smith-Cohn M, Abdullaev Z, Aldape K, Quezado M, Rosenblum M, Vanderbilt C, et al.
Free Neuropathol
. 2023 Jun;
2.
PMID: 37284624
The majority of astroblastoma occur in a cerebral location in children and young adults. Here we describe the unusual case of a 38-year-old man found to have a rapidly growing...
9.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield S, et al.
J Thorac Oncol
. 2023 May;
18(9):1165-1183.
PMID: 37182602
Introduction: Although targeted therapies have revolutionized the therapeutic landscape of lung adenocarcinomas (LUADs), disease progression on single-agent targeted therapy against known oncogenic drivers is common, and therapeutic options after disease...
10.
Petrova-Drus K, Syed M, Yu W, Hutt K, Zlotnicki A, Huang Y, et al.
J Mol Diagn
. 2023 Mar;
25(6):352-366.
PMID: 36963483
Somatic hypermutation status of the IGHV gene is essential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Unlike the conventional low-throughput method, assessment of somatic hypermutation by next-generation sequencing...